Drotaverine inhibits the formation of phosphodiesterase-IV (PDE-4) which exerts contractile action in smooth muscles. The pharmacological action of Drotaverine is rapid and direct onto the smooth muscles present in the ureter and abdominal cavity. Direct inhibition of cyclic AMP (cAMP) results in correction of calcium levels at the spastic tissues and thereby alleviate smooth muscle spasm.
Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that alleviates pain symptoms by inhibition of pain mediators associated with cyclooxygenase pathway.

Drotaverine + Mefenamic acid is contraindicated in patients with porphyria, severe hepatic, renal and CVD disorders. Drotaverine + Mefenamic acid should not be prescribed to patients with active bleeding disorder and severe peptic ulcer.

Drotaverine + Mefenamic acid may interact with analgesics, anti-muscarinics, Levodopa, benzodiazepines and other NSAIDs.

For Spasms (Adults):
Consider administration of 40-80 mg of Drotaverine + Mefenamic acid, thrice daily.
For Spasms (Pediatrics):
For children, 1-6 years of age, consider daily administration of 20 mg of Drotaverine + Mefenamic acid, three to four times.
For children over six years of age, consider administration of 40 mg of Drotaverine + Mefenamic acid, thrice daily.

Drotaverine + Mefenamic acid can be taken before or after food intake